{
    "nct_id": "NCT03456063",
    "official_title": "A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment With Atezolizumab or Placebo in Combination With Platinum-Based Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer",
    "inclusion_criteria": "Inclusion criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Histologically or cytologically confirmed, resectable Stage II, IIIA, or Select IIIB (T3N2 only) NSCLC of squamous or non-squamous histology. Staging should be based on the 8th edition of the AJCC/UICC staging system\n* Evaluation by an attending thoracic surgeon to confirm eligibility for an R0 resection with curative intent\n* Adequate pulmonary and cardiac function to undergo surgical resection\n* Measurable disease as defined by RECIST v1.1\n* Adequate hematologic and end organ function\n* Negative HIV test at screening\n* Negative for active HBV and HCV at screening\n* Adequate tissue for PD-L1 IHC assessment\n\nExclusion criteria:\n\n* NSCLC with histology of large cell neuroendocrine carcinoma or sarcomatoid carcinoma\n* Mixed NSCLC and small cell lung cancer histology\n* Any prior therapy for lung cancer\n* Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated expected curative outcome\n* Non-squamous NSCLC histology with activating ALK and EGFR mutation\n* Pregnant or lactating women\n* History of autoimmune disease\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or evidence of active of active pneumonitis on screening chest Computed Tomography (CT) scan\n* Prior treatment with cluster of differentiation 137 (CD137) agonist or immune checkpoint blockade therapies, anti-programmed-death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibody\n* Severe infection within 4 weeks prior to randomization\n* Significant history of cardiovascular disease\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}